Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STK17B | O94768 | 1/20 | 0.49 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.46 |
| ▸ | DRD2 | P14416 | 7/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.42 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.42 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.42 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.42 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.42 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.42 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 2/20 | 0.40 |
| ▸ | YTHDC1 | Q96MU7 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17150783 | 0.92 | P2RX7 (0.45) | STK17BSTK17AHDAC1HDAC2DRD2 | |
| SCHEMBL22347128 | 0.90 | STK17B (0.47) | STK17BSTK17AHDAC1HDAC2DRD2 | |
| SCHEMBL27410500 | 0.86 | STK17B (0.45) | STK17BSTK17ADRD2P2RX7HDAC6 | |
| SCHEMBL4644008 | 0.85 | DRD2 (0.45) | STK17BSTK17ADRD2P2RX7HDAC6 | |
| SCHEMBL4640672 | 0.83 | STK17B (0.46) | STK17BSTK17ADRD2P2RX7HDAC6 | |
| SCHEMBL26347131 | 0.81 | HDAC6 (0.56) | HDAC1HDAC2P2RX7HDAC8HDAC3 | |
| SCHEMBL8135319 | 0.78 | TLR7 (0.45) | STK17BSTK17ADRD2BRD4 | |
| SCHEMBL4640082 | 0.78 | FGFR1 (0.47) | STK17BSTK17ADRD2P2RX7HDAC6 | |
| SCHEMBL22359200 | 0.77 | ADCY5 (0.57) | — | |
| SCHEMBL22412661 | 0.77 | P2RX7 (0.55) | HDAC1HDAC2P2RX7HDAC8HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230302150-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | AMBRX, INC. (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230302150-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | AMBRX, INC. (US) | 2023-09-28 | — | — | US | disclosed |
| CN-116457023-A | antibody-TLR agonist conjugates, methods and uses thereof | AMBRX公司 | 2023-07-18 | — | — | CN | disclosed |
| CN-113660957-A | Compositions, methods, and uses comprising antibody-TLR agonist conjugates | AMBRX公司 | 2021-11-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230302150-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | TLR3, TLR1, TLR9 | STK17B 787/4885STK17A 459/4885HDAC1 2165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.